Leading Indian pharmaceutical company DIVI’s Laboratories has experienced rapid expansion in recent years. The business has been growing its footprint in both domestic and foreign markets while placing a strong emphasis on research and development. Due to this, investor interest has increased, and many analysts believe the share price of the company will rise in the future.
The current market position and financial performance of DIVI’s LABORATORIES will be examined in this article, and we will also project the company’s share price objective for the years 2023 to 2030. We’ll also look at elements like market trends, rivalry, and legislative changes that could affect the company’s performance. This post will provide information whether you are a long-term investor or just curious about the pharmaceutical sector.
CLICK HERE TO KNOW:
DIVI’s LAB IN RECENT NEWS
- According to momentum indicators, Divi’s Labs is expected to experience a 6-7% decline in the near future.
DIVI’s LAB SHARE PRICE TARGET 2023
|DIVI’s LAB SHARE PRICE TARGET 2023||Maximum Price||Minimum Price|
DIVI’s LABORATORIES share price predictions for 2023, it is clear that the company is expected to experience a strong bullish uptrend throughout the year. The maximum share price is forecasted to reach ₹5,021.34 in December 2023, representing a growth percentage of over 131% from the minimum price in May 2023. Even during the months with the lowest predicted share prices, such as May and June, the company is still expected to experience steady growth compared to the previous months.
Overall, the forecasted share price target for DIVI’s LABORATORIES in 2023 is very optimistic, with a potential for significant gains for investors. The company’s strong financial performance and expansion plans in both domestic and international markets are likely to fuel this growth. However, it is important to note that there may be external factors that could affect these predictions, such as changes in regulatory policies or market conditions.
DIVI’s LABORATORIES SHARE PRICE TARGET 2024
|DIVI’s LAB SHARE PRICE TARGET 2024||Maximum Price||Minimum Price|
In 2024, DIVI’s LABORATORIES is expected to continue its growth trend, albeit with a wider range compared to the previous year. The maximum price target for the year is forecasted to be ₹7,030.10 in December, while the minimum price is expected to be ₹1,037.03 in January. This represents a significant range of prices, reflecting a potentially volatile market for the company.
Despite this volatility, the company is still expected to experience steady growth throughout the year, with the maximum share price target increasing by over 32% from the previous year’s forecast. This growth is likely due to the company’s continued focus on research and development, as well as its expansion into new markets.
However, investors should still exercise caution and consider external factors that may affect the share price, such as changes in regulatory policies or global economic conditions. Overall, the forecasted share price target for DIVI’s LABORATORIES in 2024 is positive, with a potential for significant gains for those who invest wisely and manage their risks effectively.
DIVI’s LABORATORIES SHARE PRICE TARGET 2025
|DIVI’s LAB SHARE PRICE TARGET 2025||Maximum Price||Minimum Price|
In 2025, Divi’s Laboratories is expected to continue its bullish trend with a predicted maximum price of ₹8,527.62 and a minimum price of ₹6,559.71. The company’s share price is projected to start the year strong, with a maximum price of ₹7,170.70 in January and a minimum price of ₹5,515.92. The share price may continue to climb throughout the year, with a projected maximum price of ₹8,360.41 in November, marking a growth percentage of over 40% from the start of the year. Overall, the uptrend in the share price of Divi’s Laboratories is expected to continue in 2025, making it an attractive investment opportunity for investors looking for growth potential in the pharmaceutical industry.
DIVI’s LABORATORIES SHARE PRICE TARGET 2026 TO 2030
|DIVI’s LAB SHARE PRICE TARGET BY||Maximum Price||Minimum Price|
Looking ahead to the next five years, the projections for DIVI’s LABORATORIES share prices are mixed. In 2026, the stock is expected to trade in the range of ₹5,969.33 to ₹4,178.53, which represents a significant decline from the previous years. However, in 2027, the share price is predicted to see a moderate increase, with the stock trading between ₹5,073.93 and ₹3,551.75. The year 2028 is expected to be a turning point, with the share price skyrocketing to a range of ₹9,133.08 to ₹6,393.15, indicating a bullish trend. The upward momentum is expected to continue into 2029, with the share price predicted to trade in the range of ₹18,760.76 to ₹13,132.53. By 2030, the share price is expected to stabilize slightly, with the stock trading between ₹20,892.66 and ₹14,624.86. It is worth noting that these projections are based on various assumptions and factors and are subject to change depending on market conditions and company performance.
FINANCIAL STRENGTH OF DIVI’s LABORATORIES (2018 TO 2022)
|ANNUAL||FY 2022||FY 2021||FY 2020||FY 2019||FY 2018|
|Total Revenue Growth (%)||29.04||25.93||9.45||27.39||-3.24|
|Total Expenses Growth (%)||23.46||15.97||15.95||17.06||1.08|
|Profit after Tax (PAT)||2,960.45||1,984.29||1,376.54||1,352.74||877.01|
|PAT Growth (%)||49.19||44.15||1.76||54.24||-17.30|
|Operating Profit Margin (%)||41.12||38.26||33.84||37.57||31.67|
|Net Profit Margin (%)||33.04||28.47||25.51||27.34||22.53|
|Basic EPS (₹)||111.52||74.75||51.85||50.96||33.04|
According to DIVI’s LABORATORIES’ financial bank statement, the company has witnessed significant growth over the past five years. The total revenue has been consistently increasing year on year, with the maximum revenue growth of 29.04% in FY 2022. The total expenses have also grown, but not at the same pace as revenue, leading to improved operating profit margins. The net profit margins have also shown a positive trend, with a maximum of 33.04% in FY 2022, indicating that the company is effectively managing its expenses. The company’s profit after tax (PAT) has grown consistently over the past five years, with a maximum growth of 49.19% in FY 2022. The basic earnings per share (EPS) have also increased significantly over the years, indicating an upward trend in the company’s profitability. These positive financial trends are indicative of the company’s strong growth potential and ability to generate profits for its shareholders.
CLICK HERE TO KNOW:
What is the maximum share price target of Divi’s Laboratories in 2026?
The maximum share price target of Divi’s Laboratories in 2026 is Rs. 5969.33
What is the maximum share price target of Divi’s Laboratories in 2027?
The maximum share price target of Divi’s Laboratories in 2027 is Rs. 5073.93
What is the maximum share price target of Divi’s Laboratories in 2028?
The maximum share price target of Divi’s Laboratories in 2028 is Rs. 9133.08
What is the maximum share price target of Divi’s Laboratories in 2029?
The maximum share price target of Divi’s Laboratories in 2029 is Rs. 18760.76
What is the maximum share price target of Divi’s Laboratories in 2030?
The maximum share price target of Divi’s Laboratories in 2030 is Rs. 20892.66
CONCLUSION: DIVI’s LABORATORIES SHARE PRICE TARGET
According to the financial statements for the previous five years, DIVI’s Laboratories’ sales, PAT, and profit have all increased significantly. For the past five years, PAT has increased on average by 38% while sales has grown at a rate of about 23% annually. Both the operational profit margin and the net profit margin have steadily increased. The business has also kept up a strong EPS ratio.
All of these things point to DIVI’s Laboratories as a flourishing business with sound financial standing. When making any investment decisions, it is crucial to take into account additional elements such market trends, competition, and regulatory changes. Before making any stock investments, it is advisable to conduct extensive research and get professional guidance.